Supplementary figure from Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Year: 2023
Type: supplementary-materials
Abstract: Correlation of tumor response over the first 12 weeks with overall survival in patients on the vemurafenib arm on BRIM3.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361918776